Skip to content

Clinical and basic research on the effect of Prolyl Glucagon-like Peptide-1 Receptor Agonist on cognitive function in patients with type 2 diabetes mellitus

Clinical and basic research on the effect of Prolyl Glucagon-like Peptide-1 Receptor Agonist on cognitive function in patients with type 2 diabetes mellitus

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108671
Enrollment
Unknown
Registered
2025-09-03
Start date
2025-09-03
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

Intervention group:he effective blood glucose management plan for patients with type 2 diabetes represented by Hengglieqing, that is, the hypoglycemic plan containing Hengglieqing.

Sponsors

HEBEI GENERAL HOSPITAL
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age: 40 years old <= age <= 80 years old, both men and women are acceptable; 2. Diagnosed as type 2 diabetes according to the WHO diagnostic criteria; 3. The patient has not used SGLT2 inhibitor drugs within 6 months; 4. No acute cerebral infarction within 3 months; 5. Voluntarily participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with type 1 or other special types of diabetes or those with acute complications of diabetes; 2. Those with combined severe infections, traumas and other stressful situations; 3. Alcohol-dependent and drug-abusing individuals; 4. Patients with combined mental disorders such as depression, and/or those who have been taking psychotropic drugs for a long time; 5. Patients with congestive heart failure and other serious cardiopulmonary diseases that require drug treatment; 6. Patients with combined tumors and tuberculosis; 7. Patients with endocrine and metabolic diseases such as abnormal thyroid, pituitary and adrenal functions; 8. Patients with combined severe visual, auditory, speech or writing impairments who cannot cooperate to complete the cognitive function examination; 9. Patients with severe liver and kidney dysfunctions; 10. Pregnant or lactating patients.

Design outcomes

Primary

MeasureTime frame
MOCA;MMSE;ADL;

Countries

China

Contacts

Public ContactShuchun Chen

Hebei Provincial People's Hospital

chenshuc2014@163.com+86 138 3316 6283

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026